AB2004 Deputy Sheriff Peace Officer Status

California Governor signed AB2004 into law, amending Penal Code Section 830.1 to clarify or expand peace officer status for deputy sheriffs. The bill passed the Assembly unanimously (60-0) and was read in the Senate on April 6, 2026. This legislation defines the scope of peace officer designations for deputy sheriff personnel within California law enforcement.

AB2199 - Statutory Form Power of Attorney Updates to Probate Code

California Governor signed AB2199 into law, amending the Probate Code to update statutory form power of attorney provisions. The bill adds Section 4466 and repeals and adds Section 4401 of the Probate Code. The legislation passed unanimously in both chambers (68-0 Assembly vote, 12-0 committee vote) during the 2025-2026 Regular Session. Legal professionals and consumers utilizing power of attorney documents in California will be affected by the updated statutory forms.

Corporate Litigation Investment Law (AB2305)

California Governor signed AB2305 into law on April 6, 2026, creating Article 7.5 in Chapter 4 of Division 3 of the Business and Professions Code. The new law establishes regulatory requirements for corporate investment in litigation practice and attorney participation in such arrangements. The bill passed the Assembly unanimously (68-0) after receiving a do-pass recommendation (12-0) from the Judiciary Committee.

Fishing and Hunting: Youth Program (SB1021)

California SB1021 establishes a youth fishing and hunting program by adding Section 318 to the Fish and Game Code. The bill passed the Senate on February 10, 2026, following committee review by Natural Resources and Water and Appropriations. The legislation creates a structured program to encourage youth participation in fishing and hunting activities under California fish and game regulations.

Civil Discovery Depositions Transcription Amendments

California Governor signed AB2290 on April 6, 2026, amending Section 2025.550 of the Code of Civil Procedure to modify civil discovery deposition transcription requirements. The bill passed unanimously in both chambers (68-0 in Assembly, 12-0 in committee) as a consent calendar item. This procedural change affects how oral depositions are transcribed in California civil litigation.

ALT001 drug trial for MSA-C cerebellar subtype

The National Library of Medicine registered a new clinical trial on ClinicalTrials.gov for ALT001, an investigational drug for the cerebellar subtype of Multiple System Atrophy (MSA-C). The trial is categorized as an interventional study. ClinicalTrials.gov is a publicly accessible database operated by the NIH as required under FDA regulations for clinical trial registration and results reporting.

Clinical Trial NCT07516041 Registry Entry

The National Library of Medicine registered clinical trial NCT07516041 on ClinicalTrials.gov, providing public access to study details including sponsor information, eligibility criteria, and recruitment status. The trial is listed as recruiting participants.

Acupuncture and Chinese herbal fumigation for chronic neck pain, Malaysia

ClinicalTrials.gov registered a new clinical trial (NCT07515690) evaluating acupuncture and Chinese herbal fumigation for the treatment of chronic neck pain. The study is being conducted in Malaysia and registered with the US National Library of Medicine's clinical trial database.

Clinical Trial - HPV Oropharyngeal Cancer, Medical University of South Carolina

ClinicalTrials.gov published a registry entry for a new clinical trial (NCT07513389) investigating HPV-positive oropharyngeal cancer at the Medical University of South Carolina (MUSC). The study documents participant enrollment information, eligibility criteria, and research objectives. This registry entry provides transparency into ongoing federally-funded and regulated clinical research.

Clinical Trial Study NCT07515573

NIH registered clinical trial NCT07515573 on ClinicalTrials.gov. Basic trial registration includes study identifier, registration date, and status indicating details are pending. Trial sponsors and investigators must comply with FDAAA 801 requirements for clinical trial registration and results reporting.